NCT05668364

Brief Summary

The goal of the present randomised controlled clinical trial is to compare the efficacy of a 30-minute exposition to cold, atmospheric, outdoor air on the severity of croup symptoms with exposition to indoor room air in children with mild to moderate croup receiving a single dose of dexamethasone during winter croup outbreaks.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
118

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2016

Longer than P75 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2016

Completed
4.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2021

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

December 12, 2022

Completed
17 days until next milestone

First Posted

Study publicly available on registry

December 29, 2022

Completed
Last Updated

January 11, 2023

Status Verified

January 1, 2023

Enrollment Period

4.6 years

First QC Date

December 12, 2022

Last Update Submit

January 9, 2023

Conditions

Keywords

CroupLaryngitisLaryngotracheitisLaryngotracheobronchitisPediatricsChildrenInfantCold air

Outcome Measures

Primary Outcomes (1)

  • Westley croup score at 30 minutes

    The primary outcome is the proportion of patients showing an decrease of at least 2 points in their Westley croup score at 30 minutes from triage. The 5-item Westley croup score uses a 17 points ordinal scale to assess level of consciousness (5 points), cyanosis (5 points), stridor (2 points), air entry (2 points), and chest wall retractions (3 points). Mild croup is defined as a WCS \< or = 2, moderate 3-5, severe 6-11, and impending respiratory failure or \>12.

    at 30 minutes

Secondary Outcomes (7)

  • Westley croup score at 60 minutes

    at 60 minutes

  • Pulse oxymetry

    at 0 min, at 30 and at 60 minutes from enrolment at triage

  • Respiratory rate

    at 0 min, at 30 and at 60 minutes from enrolment at triage

  • Heart rate

    at 0 min, at 30 and at 60 minutes from enrolment at triage

  • Telephone Outpatient derived score

    at the time of leaving home for the pediatric emergency department visit; at 0 min on pediatric emergency department arrival (i.e., at triage); at day 7 from the initial visit

  • +2 more secondary outcomes

Study Arms (2)

Exposition group

EXPERIMENTAL

Outdoor cold air exposure (\<10°C or \<50°F) for 30 minutes. On completion of the intervention, participants remained under observation at indoor ambient air from 30 minutes to 60 minutes from the intervention.

Other: Outdoor cold air exposure

Control group

NO INTERVENTION

Indoor ambient air exposure (24-25°C or 75-77°C). Participants remained under observation at indoor ambient until 60 minutes from triage.

Interventions

Exposure to outdoor cold air (\<10°C or \<50°F, intervention group) for 30 minutes. On completion of the intervention, participants remained under observation at indoor ambient air from 30 minutes to 60 minutes from the intervention.

Exposition group

Eligibility Criteria

Age3 Months - 10 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • \- children from 3 months to 10 years with clinical signs of croup and Westley croup score \> or =2

You may not qualify if:

  • Need for close monitoring
  • Need for nebulized epinephrine
  • History or physical examination suggesting any other diagnosis
  • Chronic respiratory disease (except asthma)
  • Underlying airway abnormalities
  • Immunodeficiency
  • Contraindication to steroids

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (6)

  • Gates A, Gates M, Vandermeer B, Johnson C, Hartling L, Johnson DW, Klassen TP. Glucocorticoids for croup in children. Cochrane Database Syst Rev. 2018 Aug 22;8(8):CD001955. doi: 10.1002/14651858.CD001955.pub4.

    PMID: 30133690BACKGROUND
  • Hanna J, Brauer PR, Morse E, Berson E, Mehra S. Epidemiological analysis of croup in the emergency department using two national datasets. Int J Pediatr Otorhinolaryngol. 2019 Nov;126:109641. doi: 10.1016/j.ijporl.2019.109641. Epub 2019 Aug 13.

  • Johnson DW. Croup. BMJ Clin Evid. 2014 Sep 29;2014:0321.

  • Moore M, Little P. Humidified air inhalation for treating croup. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD002870. doi: 10.1002/14651858.CD002870.pub2.

  • Bjornson CL, Williamson J, Johnson DW. Telephone Out Patient Score: The Derivation and Validation of a Telephone Follow-up Assessment Tool for Use in Clinical Research in Children With Croup. Pediatr Emerg Care. 2016 May;32(5):290-7. doi: 10.1097/PEC.0000000000000796.

  • Siebert JN, Salomon C, Taddeo I, Gervaix A, Combescure C, Lacroix L. Outdoor Cold Air Versus Room Temperature Exposure for Croup Symptoms: A Randomized Controlled Trial. Pediatrics. 2023 Sep 1;152(3):e2023061365. doi: 10.1542/peds.2023-061365.

MeSH Terms

Conditions

CroupLaryngitis

Condition Hierarchy (Ancestors)

Laryngeal DiseasesRespiratory Tract DiseasesOtorhinolaryngologic DiseasesRespiratory Tract InfectionsInfections

Study Officials

  • Johan Siebert, MD

    University Hospitals of Geneva

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Open-label randomized controlled study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Deputy Head of the Pediatric Emergency Department

Study Record Dates

First Submitted

December 12, 2022

First Posted

December 29, 2022

Study Start

November 1, 2016

Primary Completion

May 31, 2021

Study Completion

May 31, 2021

Last Updated

January 11, 2023

Record last verified: 2023-01

Data Sharing

IPD Sharing
Will share

Deidentified Individual Participant Data will be available from the corresponding author upon reasonable request, recognizing that these data will only provide results for the current trial and not for future trials. Only deidentified/anonymized data will be shared.

Shared Documents
STUDY PROTOCOL
Time Frame
6 month to 5 years after publication of results.
Access Criteria
Data will be made available from the corresponding author upon approval of a proposal and after a signed data access agreement. Deidentified participant data will be made available to qualified external researchers who will use them according to their Institutional Review Board. Data will be made available for a specified research purpose. The request proposal should include participation of a statistician.